DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Modest DP. et al.
Randomized phase III study of fluoropyrimidine (FP) plus bevacizumab (BEV) vs. FP plus irinotecan (IRI) and BEV as first-line therapy for metastatic colorectal cancer (mCRC): German AIO KRK0110 (ML22011)-study.
Annal Oncol 2017;
28 (Suppl. 03) mdx262.025
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.